Clinical trials: Cancer Cachexia (CC)
Cancer Cachexia (CC), Cancer Cachexia
To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GB18 Injection in Healthy Participants
This study is a first-in-human, randomized, double-blind, placebo-controlled, dose-escalation trial in healthy adult participants to evaluate the safety, tolerability, PK, PD, and immunogenicity of GB18.
- Conditions
- Cancer Cachexia (CC), Cancer Cachexia, Cancer Cachexia Syndrome
- Trial name
- NCT07237464
- Testing
- GB18 injection
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Shenzhen Kexing Pharmaceutical Co., Ltd.